Title

Alendronate improves bone mineral density in perinatally HIV-infected children and adolescents with low bone mineral density for age

Publication Date

2019-10-01

UMMS Affiliation

Graduate School of Nursing

Document Type

Article

Disciplines

Immune System Diseases | Infectious Disease | Musculoskeletal Diseases | Musculoskeletal, Neural, and Ocular Physiology | Musculoskeletal System | Nutritional and Metabolic Diseases | Pediatrics | Virus Diseases

Abstract

BACKGROUND: Perinatally HIV-infected (PHIV) children and adolescents with low bone mineral density (BMD) may be at higher risk of osteoporosis and fractures in later life than their uninfected peers. Bisphosphonate therapy has been shown to reduce fractures in adults with osteoporosis, but has not been formally studied in HIV-infected youth.

METHODS: Fifty-two PHIV 11- < 25 years of age with low lumbar spine (LS) BMD (Z-score < -1.5) were randomized to receive once-weekly alendronate or placebo in a double-blind cross-over study designed to assess the safety and efficacy of 48 and 96 weeks of alendronate in the US and Brazil (ClinicalTrials.gov # NCT000921557). All participants received daily calcium carbonate and vitamin D supplementation and were asked to engage in regular weight-bearing exercise. Safety and efficacy are summarized for the initial 48 weeks of the trial.

RESULTS: Grade > /= 3 abnormal laboratory values, signs, or symptoms developed in 5 of 32 (16%) participants on alendronate and 2 of 18 (11%) on placebo (p > 0.99). No cases of jaw osteonecrosis, atrial fibrillation, or non-healing fractures were reported. Mean increases (95% confidence interval) in LS BMD over 48 weeks were significantly larger on alendronate [20% (14%, 25%)] than placebo [7% (5%, 9%), p < 0.001]. Similar improvements were seen for whole body BMD.

CONCLUSIONS: In this small study in PHIV children and adolescents with low LS BMD, 48 weeks of alendronate was well-tolerated, showed no safety concerns, and significantly improved LS and whole body BMD compared to participants on vitamin D/calcium supplementation and exercise alone.

Keywords

HIV-infection, alendronate, children, low bone mineral density

DOI of Published Version

10.1093/cid/ciz957

Source

Jacobson DL, Lindsey JC, Gordon C, Hazra R, Spiegel H, Ferreira F, Amaral FR, Pagano-Therrien J, Gaur A, George K, Benson J, Siberry GK; IMPAACT P1076 Study Team. Alendronate improves bone mineral density in perinatally HIV-infected children and adolescents with low bone mineral density for age. Clin Infect Dis. 2019 Oct 1;ciz957. doi: 10.1093/cid/ciz957. [Epub ahead of print]. PMID: 31573608. Link to article on publisher's site

Journal/Book/Conference Title

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Related Resources

Link to Article in PubMed

PubMed ID

31573608

Share

COinS